⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 25, 2024CancersOpen Access

Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR)

Ciro Franzese Veronica Vernier Marco Badalamenti R. Lucchini Sara Stefanini Anna Bertolini Maryia Ilieva Luciana Di Cristina Beatrice Marini Davide Franceschini Tiziana Comito Ruggero Spoto Luca Dominici Carmela Galdieri Pietro Mancosu Stefano Tomatis Marta Scorsetti

View Full Paper

Ask AI

Bookmark

Share

Abstract

Stereotactic ablative radiotherapy (SABR) is emerging as a potential local treatment option for oligometastatic RCC. This study aims to evaluate the efficacy of SABR in patients with oligorecurrent RCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Franzese et al. (2024) studied this question.

synapsesocial.com/papers/68e5b019b6db643587549562 https://doi.org/10.3390/cancers16172963

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer2024 · 4 citations
2Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer2024 · 3 citations
3Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinomaOriginal Research · 2026
4NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).2024
5Ablative SABR for Pulmonary Oligometastases in the Era of Contemporary Systemic Therapies: Efficacy, Safety, and Optimal SequencingOriginal Research · 2026